Companies
Grand Pharmaceutical
markets SIR-Spheres Yttrium-90 microspheres (Yigantai) for selective internal radiation therapy of liver cancer, and its US DOORwaY90 clinical trial met its primary endpoint for unresectable hepatocellular carcinoma; the company is building China's largest radiopharmaceutical production base in Wuhan.
- Country
- China
sirt
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | HK$12.28 billion (2025) | flcube.com · newsfile.moomoo.com |
| Headcount | 12,614 (as of 2025) | newsfile.moomoo.com · marketscreener.com · morningstar.com.au · www1.hkexnews.hk |
| Production site | Boston, Frankfurt, Singapore, and Chengdu | grandpharm.com · www1.hkexnews.hk |
| Capacity | 14 high-standard GMP production lines at Chengdu base | www1.hkexnews.hk |
| Regulatory approval | FDA approved for unresectable HCC and colorectal cancer liver metastases | allsci.com · grandpharm.com · sirtex.com · www1.hkexnews.hk |
| Certification | Class A Radiation Safety Licence (Chengdu facility) | grandpharm.com · www1.hkexnews.hk |
Independent sources: allsci.com · flcube.com · marketscreener.com · morningstar.com.au · newsfile.moomoo.com · sirtex.com · www1.hkexnews.hk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Radiopharmaceuticals & theranostics | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.